Stay updated on Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Sign up to get notified when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.

Latest updates to the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a detailed citation of a clinical trial related to Semaglutide and SGLT-2 inhibitors in type 2 diabetes, which included erratum references.SummaryDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has been updated to include new identifiers related to a clinical trial for diabetes treatment, while significant details about the trial's aim and inclusion/exclusion criteria have been removed.SummaryDifference10%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
Stay in the know with updates to Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.